T0070907 NEW
| Price | $45 | $53 | $93 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-15 |
Product Details
| Product Name: T0070907 | CAS No.: 313516-66-4 |
| Purity: 99.95% | Supply Ability: 10g |
| Release date: 2024/11/15 |
Product Introduction
Bioactivity
| 名稱 | T0070907 |
| 描述 | T0070907(IC50=1 nM) , an effective and specific PPARγ inhibitor, with the >800-fold selectivity over PPARα and PPARδ. |
| 細(xì)胞實(shí)驗(yàn) | MTS assay(Only for Reference) |
| 激酶實(shí)驗(yàn) | Ligand Binding Assay: To determine the binding affinity of T0070907 to the PPARs, scintillation proximity assay (SPA) is performed with the following modifications. A 90-μl reaction contains SPA buffer (10 mm KH2PO4, 10 mm KH2PO4, 2 mm EDTA, 50 mm NaCl, 1 mm dithiothreitol, 2 mmCHAPS, 10% (v/v) glycerol, pH 7.1), 50 ng of GST-PPARγ (or 150 ng of GST-PPARα, GST-PPARδ), 5 nm 3H-labeled radioligands, and 5 μl of T0070907 in Me2SO. After incubation for 1 h at room temperature, 10 μl of polylysine-coated SPA beads (at 20 mg/ml in SPA buffer) are added, and the mixtureis incubated for 1 h before reading in Packard Topcount. [3H]Rosiglitazone is used for PPARγ, and [3H]GW2433 is used for PPARα and PPARδ. |
| 體內(nèi)活性 | T0070907 can attenuate the beneficial effects of lipopolysaccharide pretreatment, such as significantly improving renal insufficiency, reducing hepatocyte damage and circulatory failure, and reducing plasma interleukin-1 elevation caused by severe endotoxemia. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 50 mg/mL (180.08 mM) 1eq. HCl : 27.8 mg/mL (100 mM) |
| 關(guān)鍵字 | PPAR | inhibit | T 0070907 | Inhibitor | T-0070907 | Peroxisome proliferator-activated receptors | T0070907 |
| 相關(guān)產(chǎn)品 | PHYTOL | (S)-(+)-Ibuprofen | BADGE | Cinnamyl alcohol | Daidzein | Fenofibrate | Pioglitazone hydrochloride | 5-Aminosalicylic Acid | Naringenin | Fisetin | 2,3-Butanediol | Icariin |
| 相關(guān)庫 | 高選擇性抑制劑庫 | 抗胰腺癌化合物庫 | 經(jīng)典已知活性庫 | 神經(jīng)退行性疾病化合物庫 | 抗乳腺癌化合物庫 | 抑制劑庫 | 脂代謝化合物庫 | 抗衰老化合物庫 | 已知活性化合物庫 | 抗癌化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00/100g |
VIP5Y
|
Career Henan Chemical Co
|
2019-12-20 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY